{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:09:09Z","timestamp":1787738949837,"version":"build-2784847793"},"reference-count":38,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Few prospective benchmark studies exist to characterize the evolving contemporary real-world practice for peripheral T-cell lymphoma (PTCL). We report the patterns of first-line care and outcomes for 720 patients with systemic PTCL enrolled in 2 related prospective cohort studies, Lymphoma Epidemiology of Outcomes (LEO) from 2015 to 2020 and Molecular Epidemiology Resource (MER) from 2002 to 2015, both followed to 2024. The primary end points were event-free survival (EFS) and overall survival (OS) using Kaplan-Meier estimator and Cox regression model. Secondary end points included correlations of clinical and treatment factors with survival. The most common induction regimens were CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) based (70%), given as CHOP (36%), CHOP plus etoposide (23%), or CHOP-like plus novel agents (11.5%, including 5% BV-CHP [brentuximab plus cyclophosphamide, doxorubicin, and prednisone]). Consolidative autologous stem cell transplant was performed in 102 patients (14%). Within nodal PTCL, EFS and OS were adversely associated with International Prognostic Index 2 to 5, prognostic index for T-cell lymphoma score 1 to 4, and non\u2013anaplastic large-cell lymphoma (ALCL) subtypes. Within LEO, which captured increasing first-line etoposide and brentuximab vedotin, adding etoposide to CHOP was associated with better OS in anaplastic lymphoma kinase-negative ALCL. BV-CHP showed a trend toward OS improvement in ALCL. Patients failing EFS6 and EFS24 had 5-year subsequent OS of 12% and 17%, respectively. The inferior outcomes in non-ALCL subtypes and patients failing EFS6 and EFS24 highlight unmet needs with CHOP-based induction, where clinical trials with targeted therapy should be prioritized. This trial was registered at www.clinicaltrials.gov as NCT02736357.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018455","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T20:54:05Z","timestamp":1771448045000},"page":"3480-3493","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study"],"prefix":"10.1182","volume":"10","author":[{"given":"Jia","family":"Ruan","sequence":"first","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-6452","authenticated-orcid":false,"given":"Zhengming","family":"Chen","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa C.","family":"Larson","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-5953","authenticated-orcid":false,"given":"N. Nora","family":"Bennani","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-3662","authenticated-orcid":false,"given":"Pamela","family":"Allen","sequence":"additional","affiliation":[{"name":"4Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9865-4517","authenticated-orcid":false,"given":"Eric","family":"Mou","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Oncology, University of Iowa, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9371-6777","authenticated-orcid":false,"given":"Danielle","family":"Wallace","sequence":"additional","affiliation":[{"name":"6Wilmot Cancer Institute, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-0670","authenticated-orcid":false,"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"8Sylvester Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7082-1846","authenticated-orcid":false,"given":"Luis E.","family":"Malpica Castillo","sequence":"additional","affiliation":[{"name":"9Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Jaye","sequence":"additional","affiliation":[{"name":"4Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-452X","authenticated-orcid":false,"given":"Francisco","family":"Vega","sequence":"additional","affiliation":[{"name":"10Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5566-0864","authenticated-orcid":false,"given":"Giorgio","family":"Inghirami","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Pongas","sequence":"additional","affiliation":[{"name":"8Sylvester Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Akkad","sequence":"additional","affiliation":[{"name":"9Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-9932","authenticated-orcid":false,"given":"Carla","family":"Casulo","sequence":"additional","affiliation":[{"name":"6Wilmot Cancer Institute, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-6481","authenticated-orcid":false,"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"4Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"1Meyer Cancer Center, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"6Wilmot Cancer Institute, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0459-6609","authenticated-orcid":false,"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-3990","authenticated-orcid":false,"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"9Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-4808","authenticated-orcid":false,"given":"Andrew L.","family":"Feldman","sequence":"additional","affiliation":[{"name":"11Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"7","key":"2026052610364961400_bib1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ajh.24791","article-title":"The aggressive peripheral T-cell lymphomas: 2017","volume":"92","author":"Armitage","year":"2017","journal-title":"Am J Hematol"},{"issue":"25","key":"2026052610364961400_bib2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026052610364961400_bib3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2026052610364961400_bib4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2026052610364961400_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11899-024-00727-w","article-title":"Update on T-cell lymphoma epidemiology","volume":"19","author":"Chen","year":"2024","journal-title":"Curr Hematol Malig Rep"},{"issue":"9","key":"2026052610364961400_bib6","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"issue":"25","key":"2026052610364961400_bib7","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026052610364961400_bib8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026052610364961400_bib9","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"issue":"11","key":"2026052610364961400_bib10","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3324\/haematol.2021.279426","article-title":"Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study","volume":"107","author":"Garc\u00eda-Sancho","year":"2022","journal-title":"Haematologica"},{"issue":"20","key":"2026052610364961400_bib11","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-10-1214","article-title":"Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary","volume":"16","author":"Malik","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2026052610364961400_bib12","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1634\/theoncologist.2015-0043","article-title":"Romidepsin for the treatment of peripheral T-cell lymphoma","volume":"20","author":"Iyer","year":"2015","journal-title":"Oncologist"},{"issue":"21","key":"2026052610364961400_bib13","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1158\/1078-0432.CCR-12-1803","article-title":"U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma","volume":"18","author":"de Claro","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2026052610364961400_bib14","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2026052610364961400_bib15","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood.2023021789","article-title":"Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs)","volume":"144","author":"Moskowitz","year":"2024","journal-title":"Blood"},{"issue":"10168","key":"2026052610364961400_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"2026052610364961400_bib17","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1634\/theoncologist.2019-0098","article-title":"FDA approval summary: brentuximab vedotin in first-line treatment of peripheral T-cell lymphoma","volume":"24","author":"Richardson","year":"2019","journal-title":"Oncologist"},{"issue":"10","key":"2026052610364961400_bib18","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2026052610364961400_bib19","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and ASCT on survival among patients aged &lt;65 years with stage II to IV PTCL: a population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2026052610364961400_bib20","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1016\/S2352-3026(25)00011-0","article-title":"Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study","volume":"12","author":"Malpica","year":"2025","journal-title":"Lancet Haematol"},{"issue":"5","key":"2026052610364961400_bib21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/hon.3074","article-title":"Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: report from the prospective international T-cell lymphoma project","volume":"40","author":"Chiattone","year":"2022","journal-title":"Hematol Oncol"},{"issue":"1","key":"2026052610364961400_bib22","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/bjh.19433","article-title":"Long-term outcome of peripheral T-cell lymphomas: ten-year follow-up of the International Prospective T-cell Project","volume":"205","author":"Civallero","year":"2024","journal-title":"Br J Haematol"},{"issue":"3","key":"2026052610364961400_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood.2020010387","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026052610364961400_bib24","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.30416","article-title":"A prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"2026052610364961400_bib25","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/ije\/dyx119","article-title":"Cohort profile: the Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) cohort study","volume":"46","author":"Cerhan","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"3","key":"2026052610364961400_bib26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ajh.27202","article-title":"The Lymphoma Epidemiology of Outcomes cohort study: design, baseline characteristics, and early outcomes","volume":"99","author":"Cerhan","year":"2024","journal-title":"Am J Hematol"},{"issue":"36","key":"2026052610364961400_bib27","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","article-title":"International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma","volume":"35","author":"Maurer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026052610364961400_bib28","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"2026052610364961400_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ajh.25674","article-title":"Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas","volume":"95","author":"Foss","year":"2020","journal-title":"Am J Hematol"},{"issue":"9","key":"2026052610364961400_bib30","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2015.63.5540","article-title":"Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States","volume":"34","author":"Adams","year":"2016","journal-title":"J Clin Oncol"},{"issue":"18","key":"2026052610364961400_bib31","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"24","key":"2026052610364961400_bib32","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/bloodadvances.2017010819","article-title":"Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma","volume":"1","author":"Kim","year":"2017","journal-title":"Blood Adv"},{"issue":"19","key":"2026052610364961400_bib33","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1182\/bloodadvances.2020003971","article-title":"Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2","volume":"6","author":"Savage","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2026052610364961400_bib34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/bloodadvances.2024014674","article-title":"Global outcomes and prognosis for relapsed\/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium","volume":"9","author":"Han","year":"2025","journal-title":"Blood Adv"},{"issue":"19","key":"2026052610364961400_bib35","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/blood.2024025681","article-title":"Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis","volume":"144","author":"Abro","year":"2024","journal-title":"Blood"},{"issue":"19","key":"2026052610364961400_bib36","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"15","key":"2026052610364961400_bib37","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2026052610364961400_bib38","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3480\/2519369\/blooda_adv-2025-018455-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3480\/2519369\/blooda_adv-2025-018455-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:37:00Z","timestamp":1779806220000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/10\/3480\/566660\/Patterns-of-care-and-clinical-outcomes-in-systemic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018455","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,26]]},"published":{"date-parts":[[2026,5,14]]}}}